The Quantellect read.As of Nov 19, 2026, 10 active firms cover Iovance Biotherapeutics Inc: 8 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $7.00 to $20.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $13.20 sits 76% above the current $7.49. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.04 next quarter toward $-0.11 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy880%
Neutral220%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$13.20
+76.4% upside
Average target across 10 active firms as of Nov 19, 2026 vs $7.49 current
Highest Target$20.00
Average Target$13.20
Lowest Target$7.00
Detailed analyst forecasts for IOVA
Showing 1–10 of 10 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 8 of 10 active firms rate IOVA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IOVA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.08 – $-0.02 · 7 analysts · -78% YoY
Next period, 7 analysts expect Iovance Biotherapeutics Inc to earn $-0.04 a share (range $-0.08 – $-0.02), versus $-0.19 a year earlier. Full-year consensus is $-0.38, growing to $-0.11 the year after.
REVENUE · NEXT QUARTER
$133.9M
Range $124.9M – $145.2M · 7 analysts · +87% YoY
Revenue is expected to reach $133.9M (range $124.9M – $145.2M), +87.5% year-over-year. Full-year consensus is $418.6M, rising to $593.8M next year.
Top analysts covering Iovance Biotherapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IOVA.
#1
Peter Lawson
Barclays · Rank #89
Buy
$4.00-46.6% to target
Overall win rate
45%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #104
Buy
$14.00+87.0% to target
Overall win rate
43%
+ Follow
#3
Joseph Catanzaro
Piper Sandler · Rank #353
Neutral
$6.00-19.8% to target
Overall win rate
41%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$20.00+167.2% to target
Overall win rate
34%
+ Follow
#5
Reni J. Benjamin
JMP Securities · Rank #489
Buy
$8.00+6.9% to target
Overall win rate
29%
+ Follow
IOVA stock forecast FAQ
What is IOVA's average 12-month price target?+
The 10 active firms with a live target average $13.20 for Iovance Biotherapeutics Inc over the next 12 months, ranging from a $20.00 high to a $7.00 low, as of Nov 19, 2026.
Is IOVA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IOVA?+
The Street-high target is $20.00 (HC Wainwright & Co.), and the Street-low is $7.00 (UBS). The average of all 10 active-firm targets is $13.20.
How many active Wall Street firms cover IOVA?+
10 active firms have a recognized rating on Iovance Biotherapeutics Inc as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IOVA?+
Among analysts who currently cover IOVA, Peter Lawson of Barclays has the strongest overall Quantellect track record (Rank #89). Their current call is Buy with a $4.00 target.
What is Iovance Biotherapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.08 – $-0.02) across 7 analysts. Full-year EPS is projected at $-0.38, rising to $-0.11 the following year.
How much revenue is Iovance Biotherapeutics Inc expected to report next quarter?+
Consensus revenue is $133.9M (range $124.9M – $145.2M). Full-year revenue is projected at $418.6M, growing to $593.8M next year.
Have analysts been upgrading or downgrading IOVA lately?+
As of Nov 19, 2026, 8 of 10 active firms rate IOVA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IOVA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.